Akt signaling pathway: a potential therapy for Alzheimer’s disease through glycogen synthase kinase 3 beta inhibition
Abstract Alzheimer’s disease (AD) is a form of dementia marked by the accumulation of neuritic plaques and neurofibrillary tangles through the action of GSK-3β with both significant epidemiological and clinical impact. Current pharmacological treatment approaches are focused on symptomatic relief an...
Main Authors: | Joshua Limantoro, Bryan Gervais de Liyis, Jane Carissa Sutedja |
---|---|
Format: | Article |
Language: | English |
Published: |
SpringerOpen
2023-11-01
|
Series: | The Egyptian Journal of Neurology, Psychiatry and Neurosurgery |
Subjects: | |
Online Access: | https://doi.org/10.1186/s41983-023-00751-2 |
Similar Items
-
Glycogen synthase kinase 3 (GSK-3) and its inhibitors : drug discovery and development /
by: Martinez, Ana, 1961-, et al.
Published: (2006) -
Regulation of Phosphorylation of Glycogen Synthase Kinase 3α and the Correlation with Sperm Motility in Human
by: Seung Hyun Park, et al.
Published: (2024-04-01) -
Yeast Glycogen Synthase Kinase-3 Pathway Inhibitors from an Organic Extract of Streptomyces sp.
by: Cheenpracha, Sarot, et al.
Published: (2009) -
Clinical activity of 9-ING-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, in refractory adult T-Cell leukemia/lymphoma
by: Andrew Hsu, et al.
Published: (2022-12-01) -
Glycogen synthase kinase-3: A promising therapeutic target for Fragile X Syndrome
by: Marjelo M. Mines, et al.
Published: (2011-11-01)